Linked Life Data

17885079

Source:http://linkedlifedata.com/resource/pubmed/id/17885079

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-12-24
pubmed:databankReference
pubmed:abstractText
The role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial, and there has been little attempt to quantitate interobserver variability. Diagnostic bone marrow trephine biopsy specimens from 370 patients with ET by Polycythemia Vera Study Group (PVSG) criteria were assessed by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to the World Health Organization (WHO) classification. Our results show substantial interobserver variability, particularly for overall diagnosis and individual cellular characteristics such as megakaryocyte morphology. Reticulin grade was the dominant independent predictor of WHO diagnostic category for all 3 hematopathologists. Factor analysis identified 3 independent factors likely to reflect underlying biologic processes. One factor related to overall and lineage-specific cellularity and was significantly associated with JAK2 V617F status (P < .001), a second factor related to megakaryocyte clustering, and a third was associated with the fibrotic process. No differences could be discerned between patients labeled as having "prefibrotic myelofibrosis" or "true ET" in clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation. These results show that histologic criteria described in the WHO classification are difficult to apply reproducibly and question the validity of distinguishing true ET from prefibrotic myelofibrosis on the basis of subjective morphologic criteria. This study was registered at http://isrctn.org as #72251782 and at http://eudract.emea.europa.eu/ as #2004-000245-38.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
111
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
60-70
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17885079-Adult, pubmed-meshheading:17885079-Antineoplastic Agents, pubmed-meshheading:17885079-Aspirin, pubmed-meshheading:17885079-Biopsy, pubmed-meshheading:17885079-Blood Cell Count, pubmed-meshheading:17885079-Drug Therapy, Combination, pubmed-meshheading:17885079-Hematology, pubmed-meshheading:17885079-Humans, pubmed-meshheading:17885079-Hydroxyurea, pubmed-meshheading:17885079-Megakaryocytes, pubmed-meshheading:17885079-Observer Variation, pubmed-meshheading:17885079-Pathology, Clinical, pubmed-meshheading:17885079-Platelet Aggregation Inhibitors, pubmed-meshheading:17885079-Polycythemia Vera, pubmed-meshheading:17885079-Primary Myelofibrosis, pubmed-meshheading:17885079-Prospective Studies, pubmed-meshheading:17885079-Quinazolines, pubmed-meshheading:17885079-Thrombocytosis
pubmed:year
2008
pubmed:articleTitle
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
pubmed:affiliation
Department of Cellular Pathology, Newcastle-upon-Tyne Hospitals National Health Service (NHS) Foundation Trust and Newcastle University, Newcastle-upon-Tyne, UK.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study